Scrip RSS Feedhttps://insights.citeline.comThe Latest News & Analysis from ScripFri, 11 Sep 2026 10:24:31 +0000en1hourly1 https://insights.citeline.com/scrip/leadership/executives-on-the-move/executives-on-the-move-vertex-expands-its-leadership-team-following-crinetics-acquisition-SDW3RQF5GBAGVHP22PXE3FY5QU/<![CDATA[Executives On The Move: Vertex Expands Its Leadership Team Following Crinetics Acquisition]]>premium

      
]]> https://feeds.feedblitz.com/~/968958974/0/scrip~Executives-On-The-Move-Vertex-Expands-Its-Leadership-Team-Following-Crinetics-Acquisition/https://insights.citeline.com/scrip/leadership/executives-on-the-move/executives-on-the-move-vertex-expands-its-leadership-team-following-crinetics-acquisition-SDW3RQF5GBAGVHP22PXE3FY5QU/
      
]]> Fri, 11 Sep 2026 09:26:19 +0000 https://insights.citeline.com/scrip/therapeutic-category/blood-and-clotting/china-grants-global-first-approval-to-hengruis-oral-tpo-ra-in-thrombocytopenia-CA4M2XPN4ZGJZI3T335IKT75SE/<![CDATA[China Grants Global-First Approval To Hengrui’s Oral TPO-RA In Thrombocytopenia]]>premium

      
]]> https://feeds.feedblitz.com/~/968958977/0/scrip~China-Grants-GlobalFirst-Approval-To-Hengrui%e2%80%99s-Oral-TPORA-In-Thrombocytopenia/https://insights.citeline.com/scrip/therapeutic-category/blood-and-clotting/china-grants-global-first-approval-to-hengruis-oral-tpo-ra-in-thrombocytopenia-CA4M2XPN4ZGJZI3T335IKT75SE/
      
]]> Fri, 11 Sep 2026 09:20:28 +0000 https://insights.citeline.com/scrip/leadership/takedas-plump-to-retire-as-rd-head-after-shepherding-new-drugs-to-market-HD75BZ3YFFCGRNCFNVLBF7R3V4/<![CDATA[Takeda’s Plump To Retire As R&D Head After Shepherding New Drugs To Market ]]>premium

      
]]> https://feeds.feedblitz.com/~/968941604/0/scrip~Takeda%e2%80%99s-Plump-To-Retire-As-RD-Head-After-Shepherding-New-Drugs-To-Market/https://insights.citeline.com/scrip/leadership/takedas-plump-to-retire-as-rd-head-after-shepherding-new-drugs-to-market-HD75BZ3YFFCGRNCFNVLBF7R3V4/
      
]]> Thu, 10 Sep 2026 21:15:43 +0000 https://insights.citeline.com/scrip/advanced-therapies/shionogi-considers-redasemtides-future-after-mixed-phase-ii-results-ZMES7TVOPJFKHOXWIPWYUXKXY4/<![CDATA[Shionogi Considers Redasemtide’s Future After Mixed Phase II Readouts]]>premium

      
]]> https://feeds.feedblitz.com/~/968948720/0/scrip~Shionogi-Considers-Redasemtide%e2%80%99s-Future-After-Mixed-Phase-II-Readouts/https://insights.citeline.com/scrip/advanced-therapies/shionogi-considers-redasemtides-future-after-mixed-phase-ii-results-ZMES7TVOPJFKHOXWIPWYUXKXY4/
      
]]> Fri, 11 Sep 2026 02:52:45 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/kyowa-kirin-encouraged-by-namd-eye-drop-results-despite-missed-endpoint-4B47M6BMM5DLZGFHL3LR7XE4WU/<![CDATA[Kyowa Kirin Encouraged By nAMD Eye Drop Results Despite Missed Endpoint]]>premium

      
]]> https://feeds.feedblitz.com/~/968948126/0/scrip~Kyowa-Kirin-Encouraged-By-nAMD-Eye-Drop-Results-Despite-Missed-Endpoint/https://insights.citeline.com/scrip/r-and-d/clinical-trials/kyowa-kirin-encouraged-by-namd-eye-drop-results-despite-missed-endpoint-4B47M6BMM5DLZGFHL3LR7XE4WU/
      
]]> Fri, 11 Sep 2026 02:08:34 +0000 https://insights.citeline.com/scrip/rare-diseases/roche-pushes-ahead-with-pipeline-in-a-product-plans-for-enspryng-FEW33KXNRNGJNGYIBVS57O4LAA/<![CDATA[Roche Pushes Ahead With Pipeline-In-A-Product Plans For Enspryng ]]>premium

      
]]> https://feeds.feedblitz.com/~/968929211/0/scrip~Roche-Pushes-Ahead-With-PipelineInAProduct-Plans-For-Enspryng/https://insights.citeline.com/scrip/rare-diseases/roche-pushes-ahead-with-pipeline-in-a-product-plans-for-enspryng-FEW33KXNRNGJNGYIBVS57O4LAA/
      
]]> Thu, 10 Sep 2026 13:51:09 +0000 https://insights.citeline.com/scrip/focus-on-asia/india/deal-by-deal-warburg-pincus-adds-koye-to-india-platform-push-ASP2STKNUZENLIN3ZJ4SA36ZTU/<![CDATA[Deal By Deal: Warburg Pincus Adds Koye to India Platform Push]]>premium

      
]]> https://feeds.feedblitz.com/~/968931407/0/scrip~Deal-By-Deal-Warburg-Pincus-Adds-Koye-to-India-Platform-Push/https://insights.citeline.com/scrip/focus-on-asia/india/deal-by-deal-warburg-pincus-adds-koye-to-india-platform-push-ASP2STKNUZENLIN3ZJ4SA36ZTU/
      
]]> Thu, 10 Sep 2026 15:01:12 +0000 https://insights.citeline.com/scrip/new-products/bayers-hyrnuo-gets-first-line-nsclc-indication-equal-footing-with-hernexeos-T4WMBPJ7SNE7TN2M5E2NH64ZSQ/<![CDATA[Bayer’s Hyrnuo Gets First-Line NSCLC Indication, Equal Footing With Hernexeos]]>premium

      
]]> https://feeds.feedblitz.com/~/968940866/0/scrip~Bayer%e2%80%99s-Hyrnuo-Gets-FirstLine-NSCLC-Indication-Equal-Footing-With-Hernexeos/https://insights.citeline.com/scrip/new-products/bayers-hyrnuo-gets-first-line-nsclc-indication-equal-footing-with-hernexeos-T4WMBPJ7SNE7TN2M5E2NH64ZSQ/
      
]]> Thu, 10 Sep 2026 20:38:59 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/biohavens-newly-out-licensed-epilepsy-drug-put-on-a-partial-clinical-hold-64XGDHHTZNENZGMW7VKB6IVSME/<![CDATA[Biohaven’s Newly Out-Licensed Epilepsy Drug Put On A Partial Clinical Hold]]>premium

      
]]> https://feeds.feedblitz.com/~/968941940/0/scrip~Biohaven%e2%80%99s-Newly-OutLicensed-Epilepsy-Drug-Put-On-A-Partial-Clinical-Hold/https://insights.citeline.com/scrip/r-and-d/clinical-trials/biohavens-newly-out-licensed-epilepsy-drug-put-on-a-partial-clinical-hold-64XGDHHTZNENZGMW7VKB6IVSME/
      
]]> Thu, 10 Sep 2026 21:40:20 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/amgen-stands-to-broaden-imdelltra-market-with-first-line-maintenance-es-sclc-data-5TYD6LOX3JBEFEXQCLKJLVHHRM/<![CDATA[Amgen Stands To Broaden Imdelltra Market With First-Line Maintenance ES-SCLC Data]]>premium

      
]]> https://feeds.feedblitz.com/~/968849804/0/scrip~Amgen-Stands-To-Broaden-Imdelltra-Market-With-FirstLine-Maintenance-ESSCLC-Data/https://insights.citeline.com/scrip/r-and-d/clinical-trials/amgen-stands-to-broaden-imdelltra-market-with-first-line-maintenance-es-sclc-data-5TYD6LOX3JBEFEXQCLKJLVHHRM/
      
]]> Tue, 08 Sep 2026 20:33:47 +0000 https://insights.citeline.com/scrip/business/financing/chinese-advanced-molecular-therapy-firms-extend-funding-spree-in-august-SDBI2ZO7RZCEPM6LJPBGDAJM3A/<![CDATA[Chinese Advanced Molecular Therapy Firms Extend Funding Spree In August]]>premium

      
]]> https://feeds.feedblitz.com/~/968903018/0/scrip~Chinese-Advanced-Molecular-Therapy-Firms-Extend-Funding-Spree-In-August/https://insights.citeline.com/scrip/business/financing/chinese-advanced-molecular-therapy-firms-extend-funding-spree-in-august-SDBI2ZO7RZCEPM6LJPBGDAJM3A/
      
]]> Thu, 10 Sep 2026 03:04:58 +0000 https://insights.citeline.com/scrip/business/financing/kura-spins-out-caspian-with-50m-to-test-menin-inhibition-in-diabetes-HDRJ5Z7JVRG2TH6LBUEXLTCCCM/<![CDATA[Kura Spins Out Caspian With $50m To Test Menin Inhibition In Diabetes]]>premium

      
]]> https://feeds.feedblitz.com/~/968887238/0/scrip~Kura-Spins-Out-Caspian-With-m-To-Test-Menin-Inhibition-In-Diabetes/https://insights.citeline.com/scrip/business/financing/kura-spins-out-caspian-with-50m-to-test-menin-inhibition-in-diabetes-HDRJ5Z7JVRG2TH6LBUEXLTCCCM/
      
]]> Wed, 09 Sep 2026 16:34:38 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/after-some-big-flops-whats-next-in-cardiovascular-outcomes-studies-M7NRZVBCOJD3TE5XOXEUYZ22GQ/<![CDATA[After Some Big Flops, What’s Next In Cardiovascular Outcomes Studies?]]>premium

      
]]> https://feeds.feedblitz.com/~/968882174/0/scrip~After-Some-Big-Flops-What%e2%80%99s-Next-In-Cardiovascular-Outcomes-Studies/https://insights.citeline.com/scrip/r-and-d/clinical-trials/after-some-big-flops-whats-next-in-cardiovascular-outcomes-studies-M7NRZVBCOJD3TE5XOXEUYZ22GQ/
      
]]> Wed, 09 Sep 2026 14:45:55 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/evommune-scraps-second-evo756-program-but-presses-on-in-migraine-S7JFFAUBPVFKPJ6FESSZWQFLHE/<![CDATA[Evommune Scraps Second EVO756 Program But Presses On In Migraine]]>premium

      
]]> https://feeds.feedblitz.com/~/968871623/0/scrip~Evommune-Scraps-Second-EVO-Program-But-Presses-On-In-Migraine/https://insights.citeline.com/scrip/r-and-d/clinical-trials/evommune-scraps-second-evo756-program-but-presses-on-in-migraine-S7JFFAUBPVFKPJ6FESSZWQFLHE/
      
]]> Wed, 09 Sep 2026 13:01:24 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/structures-oral-amylin-shows-early-promise-in-first-human-test-7CNWCO4HJFFPPDXHEXFKM6Q7MQ/<![CDATA[Structure’s Oral Amylin Shows Early Promise In First Human Test]]>premium

      
]]> https://feeds.feedblitz.com/~/968871626/0/scrip~Structure%e2%80%99s-Oral-Amylin-Shows-Early-Promise-In-First-Human-Test/https://insights.citeline.com/scrip/r-and-d/clinical-trials/structures-oral-amylin-shows-early-promise-in-first-human-test-7CNWCO4HJFFPPDXHEXFKM6Q7MQ/
      
]]> Wed, 09 Sep 2026 12:57:42 +0000 https://insights.citeline.com/scrip/therapeutic-category/anticancer/priothera-seeks-partner-as-mocravimod-advances-in-phase-iii-leukemia-trial-WLHSBFXIUNHARCSCZPQFSCJUUQ/<![CDATA[Priothera Seeks Partner As Mocravimod Advances In Phase III Leukemia Trial ]]>premium

      
]]> https://feeds.feedblitz.com/~/968878271/0/scrip~Priothera-Seeks-Partner-As-Mocravimod-Advances-In-Phase-III-Leukemia-Trial/https://insights.citeline.com/scrip/therapeutic-category/anticancer/priothera-seeks-partner-as-mocravimod-advances-in-phase-iii-leukemia-trial-WLHSBFXIUNHARCSCZPQFSCJUUQ/
      
]]> Wed, 09 Sep 2026 13:47:03 +0000 https://insights.citeline.com/scrip/business/financing/solstice-launches-with-second-generation-ctla-4-inhibitor-porustobart-in-tow-7UB232ZMM5AGPB44DILLVWLM4A/<![CDATA[Solstice Launches With Second-Generation CTLA-4 Inhibitor Porustobart In Tow]]>premium

      
]]> https://feeds.feedblitz.com/~/968893910/0/scrip~Solstice-Launches-With-SecondGeneration-CTLA-Inhibitor-Porustobart-In-Tow/https://insights.citeline.com/scrip/business/financing/solstice-launches-with-second-generation-ctla-4-inhibitor-porustobart-in-tow-7UB232ZMM5AGPB44DILLVWLM4A/
      
]]> Wed, 09 Sep 2026 20:58:32 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/bms-spinout-beeline-looks-to-move-lead-candidate-into-lupus-pivotal-studies-WWQ3MUBUC5EDRD4MUU3NJISYAM/<![CDATA[BMS Spinout Beeline Looks To Move Lead Candidate Into Lupus Pivotal Studies]]>premium

      
]]> https://feeds.feedblitz.com/~/968895446/0/scrip~BMS-Spinout-Beeline-Looks-To-Move-Lead-Candidate-Into-Lupus-Pivotal-Studies/https://insights.citeline.com/scrip/r-and-d/clinical-trials/bms-spinout-beeline-looks-to-move-lead-candidate-into-lupus-pivotal-studies-WWQ3MUBUC5EDRD4MUU3NJISYAM/
      
]]> Wed, 09 Sep 2026 22:11:36 +0000 https://insights.citeline.com/scrip/focus-on-asia/india/oncology-trial-waivers-in-india-big-pharma-local-firms-navigate-path-to-faster-entry-NVPR52HDOJDXNFXYIUGBHCNG4U/<![CDATA[India Oncology Trial Waivers: How Big Pharma, Local Firms Are Navigating The Path To Faster Entry]]>premium

      
]]> https://feeds.feedblitz.com/~/968823098/0/scrip~India-Oncology-Trial-Waivers-How-Big-Pharma-Local-Firms-Are-Navigating-The-Path-To-Faster-Entry/https://insights.citeline.com/scrip/focus-on-asia/india/oncology-trial-waivers-in-india-big-pharma-local-firms-navigate-path-to-faster-entry-NVPR52HDOJDXNFXYIUGBHCNG4U/
      
]]> Tue, 08 Sep 2026 11:39:17 +0000 https://insights.citeline.com/scrip/focus-on-asia/india/chryscapitals-nil-bags-minipress-xl-steps-into-ophthalmology-in-rapid-deal-burst-U7LIE6VSV5EDZJUEPXLI6NYO5A/<![CDATA[ChrysCapital’s NIL Bags Minipress XL, Steps Into Ophthalmology In Rapid Deal Burst]]>premium

      
]]> https://feeds.feedblitz.com/~/968866526/0/scrip~ChrysCapital%e2%80%99s-NIL-Bags-Minipress-XL-Steps-Into-Ophthalmology-In-Rapid-Deal-Burst/https://insights.citeline.com/scrip/focus-on-asia/india/chryscapitals-nil-bags-minipress-xl-steps-into-ophthalmology-in-rapid-deal-burst-U7LIE6VSV5EDZJUEPXLI6NYO5A/
      
]]> Wed, 09 Sep 2026 09:43:51 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/astrazenecas-tozorakimab-positioned-for-multi-billion-opportunity-in-copd-7WVG7GLUHZAVFJF3ST4GKVYJZQ/<![CDATA[AstraZeneca’s Tozorakimab Positioned For Multi-Billion Opportunity In COPD ]]>premium

      
]]> https://feeds.feedblitz.com/~/968851007/0/scrip~AstraZeneca%e2%80%99s-Tozorakimab-Positioned-For-MultiBillion-Opportunity-In-COPD/https://insights.citeline.com/scrip/r-and-d/clinical-trials/astrazenecas-tozorakimab-positioned-for-multi-billion-opportunity-in-copd-7WVG7GLUHZAVFJF3ST4GKVYJZQ/
      
]]> Tue, 08 Sep 2026 21:39:13 +0000 https://insights.citeline.com/scrip/business/financing/brainchild-launches-with-116m-to-test-car-t-in-pediatric-brain-cancer-RPPPJSEJARHLROKMY4EJ73ERGY/<![CDATA[BrainChild Launches With $116m To Test CAR-T In Pediatric Brain Cancer]]>premium

      
]]> https://feeds.feedblitz.com/~/968821718/0/scrip~BrainChild-Launches-With-m-To-Test-CART-In-Pediatric-Brain-Cancer/https://insights.citeline.com/scrip/business/financing/brainchild-launches-with-116m-to-test-car-t-in-pediatric-brain-cancer-RPPPJSEJARHLROKMY4EJ73ERGY/
      
]]> Tue, 08 Sep 2026 11:05:00 +0000 https://insights.citeline.com/scrip/business/stock-watch/stock-watch-mrnas-cancer-win-puts-the-antivax-lobby-in-a-corner-H2U25VEO2NDU3EVQ5NDISX6UMU/<![CDATA[Stock Watch: mRNA’s Cancer Win Puts The Antivax Lobby In a Corner ]]>premium

      
]]> https://feeds.feedblitz.com/~/968835776/0/scrip~Stock-Watch-mRNA%e2%80%99s-Cancer-Win-Puts-The-Antivax-Lobby-In-a-Corner/https://insights.citeline.com/scrip/business/stock-watch/stock-watch-mrnas-cancer-win-puts-the-antivax-lobby-in-a-corner-H2U25VEO2NDU3EVQ5NDISX6UMU/
      
]]> Tue, 08 Sep 2026 13:55:08 +0000 https://insights.citeline.com/scrip/business/strategy/novartis-ma-strategy-under-spotlight-after-another-phase-iii-blow-GVSD6BYE25AFRPREXF2OYZA5UU/<![CDATA[Novartis M&A Strategy Under Spotlight After Another Phase III Blow]]>premium

      
]]> https://feeds.feedblitz.com/~/968836385/0/scrip~Novartis-MA-Strategy-Under-Spotlight-After-Another-Phase-III-Blow/https://insights.citeline.com/scrip/business/strategy/novartis-ma-strategy-under-spotlight-after-another-phase-iii-blow-GVSD6BYE25AFRPREXF2OYZA5UU/
      
]]> Tue, 08 Sep 2026 14:20:14 +0000 https://insights.citeline.com/scrip/advanced-therapies/cell-therapies/bmss-arlo-cel-shows-positive-results-in-bcma-exposed-myeloma-patients-VTDN3QJSOBFN7AUJ4T7RGP3PEQ/<![CDATA[BMS’s Arlo-Cel Shows Positive Results In BCMA-Exposed Myeloma Patients ]]>premium

      
]]> https://feeds.feedblitz.com/~/968847941/0/scrip~BMS%e2%80%99s-ArloCel-Shows-Positive-Results-In-BCMAExposed-Myeloma-Patients/https://insights.citeline.com/scrip/advanced-therapies/cell-therapies/bmss-arlo-cel-shows-positive-results-in-bcma-exposed-myeloma-patients-VTDN3QJSOBFN7AUJ4T7RGP3PEQ/
      
]]> Tue, 08 Sep 2026 19:47:19 +0000Alaric DeArment